MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
SHH pathway
SMO inhibition
medulloblastoma
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
02 11 2021
02 11 2021
Historique:
pubmed:
8
4
2021
medline:
6
11
2021
entrez:
7
4
2021
Statut:
ppublish
Résumé
Vismodegib specifically inhibits Sonic Hedgehog (SHH). We report results of a phase I/II evaluating vismodegib + temozolomide (TMZ) in immunohistochemically defined SHH recurrent/refractory adult medulloblastoma. TMZ-naïve patients were randomized 2:1 to receive vismodegib + TMZ (arm A) or TMZ (arm B). Patients previously treated with TMZ were enrolled in an exploratory cohort of vismodegib (arm C). If the safety run showed no excessive toxicity, a Simon's 2-stage phase II design was planned to explore the 6-month progression-free survival (PFS-6). Stage II was to proceed if arm A PFS-6 was ≥3/9 at the end of stage I. A total of 24 patients were included: arm A (10), arm B (5), and arm C (9). Safety analysis showed no excessive toxicity. At the end of stage I, the PFS-6 of arm A was 20% (2/10 patients, 95% unilateral lower confidence limit: 3.7%) and the study was prematurely terminated. The overall response rates (ORR) were 40% (95% CI, 12.2-73.8) and 20% (95% CI, 0.5-71.6) in arm A and B, respectively. In arm C, PFS-6 was 37.5% (95% CI, 8.8-75.5) and ORR was 22.2% (95% CI, 2.8-60.0). Among 11 patients with an expected sensitivity according to new generation sequencing (NGS), 3 had partial response (PR), 4 remained stable disease (SD) while out of 7 potentially resistant patients, 1 had PR and 1 SD. The addition of vismodegib to TMZ did not add toxicity but failed to improve PFS-6 in SHH recurrent/refractory medulloblastoma. Prediction of sensitivity to vismodegib needs further refinements.
Sections du résumé
BACKGROUND
Vismodegib specifically inhibits Sonic Hedgehog (SHH). We report results of a phase I/II evaluating vismodegib + temozolomide (TMZ) in immunohistochemically defined SHH recurrent/refractory adult medulloblastoma.
METHODS
TMZ-naïve patients were randomized 2:1 to receive vismodegib + TMZ (arm A) or TMZ (arm B). Patients previously treated with TMZ were enrolled in an exploratory cohort of vismodegib (arm C). If the safety run showed no excessive toxicity, a Simon's 2-stage phase II design was planned to explore the 6-month progression-free survival (PFS-6). Stage II was to proceed if arm A PFS-6 was ≥3/9 at the end of stage I.
RESULTS
A total of 24 patients were included: arm A (10), arm B (5), and arm C (9). Safety analysis showed no excessive toxicity. At the end of stage I, the PFS-6 of arm A was 20% (2/10 patients, 95% unilateral lower confidence limit: 3.7%) and the study was prematurely terminated. The overall response rates (ORR) were 40% (95% CI, 12.2-73.8) and 20% (95% CI, 0.5-71.6) in arm A and B, respectively. In arm C, PFS-6 was 37.5% (95% CI, 8.8-75.5) and ORR was 22.2% (95% CI, 2.8-60.0). Among 11 patients with an expected sensitivity according to new generation sequencing (NGS), 3 had partial response (PR), 4 remained stable disease (SD) while out of 7 potentially resistant patients, 1 had PR and 1 SD.
CONCLUSION
The addition of vismodegib to TMZ did not add toxicity but failed to improve PFS-6 in SHH recurrent/refractory medulloblastoma. Prediction of sensitivity to vismodegib needs further refinements.
Identifiants
pubmed: 33825892
pii: 6213882
doi: 10.1093/neuonc/noab087
pmc: PMC8563312
doi:
Substances chimiques
Anilides
0
Hedgehog Proteins
0
HhAntag691
0
Pyridines
0
Temozolomide
YF1K15M17Y
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1949-1960Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Science. 2009 Oct 23;326(5952):572-4
pubmed: 19726788
Oncotarget. 2016 Feb 9;7(6):7134-48
pubmed: 26784250
Control Clin Trials. 1989 Mar;10(1):1-10
pubmed: 2702835
Bull Cancer. 2016 Dec;103(12):1050-1056
pubmed: 27866682
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
Acta Neuropathol. 2011 Mar;121(3):381-96
pubmed: 21267586
Neuro Oncol. 2018 Feb 19;20(3):400-410
pubmed: 29016837
Cancer. 2007 Oct 1;110(7):1542-50
pubmed: 17705175
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
J Neurooncol. 2016 Jun;128(2):235-40
pubmed: 26940908
N Engl J Med. 2009 Sep 17;361(12):1173-8
pubmed: 19726761
Cancer. 1981 Jan 1;47(1):207-14
pubmed: 7459811
Acta Neuropathol. 2016 Jun;131(6):821-31
pubmed: 27040285
Acta Neuropathol. 2012 Apr;123(4):615-26
pubmed: 22057785
Neurochirurgie. 2021 Feb;67(1):76-82
pubmed: 30554773
Neuro Oncol. 2013 Sep;15(9):1236-43
pubmed: 23857707
Neuro Oncol. 2014 May;16(5):748-53
pubmed: 24482446
Oncotarget. 2018 Mar 30;9(24):16619-16633
pubmed: 29682173
Mol Cancer Ther. 2016 May;15(5):866-76
pubmed: 26823493
Sci Transl Med. 2010 Sep 29;2(51):51ra70
pubmed: 20881279
Cancer Cell. 2014 Mar 17;25(3):393-405
pubmed: 24651015
J Mol Diagn. 2020 Jul;22(7):957-966
pubmed: 32380172
Trends Pharmacol Sci. 2015 Aug;36(8):547-58
pubmed: 26072120
J Clin Oncol. 2014 Mar 20;32(9):886-96
pubmed: 24493713
Drugs. 2019 Feb;79(2):207-213
pubmed: 30666593
Nat Chem Biol. 2015 Apr;11(4):246-55
pubmed: 25785427
Neuro Oncol. 2017 Oct 19;19(11):1542-1552
pubmed: 28605510
Cancer. 1994 Oct 15;74(8):2352-60
pubmed: 7922986
Clin Cancer Res. 2015 Feb 1;21(3):585-93
pubmed: 25473003
Pediatr Blood Cancer. 2020 Jan;67(1):e28032
pubmed: 31595663
J Neuropathol Exp Neurol. 2020 Apr 1;79(4):437-447
pubmed: 32053195
Clin Cancer Res. 2013 Nov 15;19(22):6305-12
pubmed: 24077351
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4505-10
pubmed: 16537363
J Neurooncol. 2019 Aug;144(1):231-233
pubmed: 31187320
Mol Oncol. 2015 Feb;9(2):389-97
pubmed: 25306392
Cells. 2018 Dec 14;7(12):
pubmed: 30558232
Eur J Cancer. 2005 Jun;41(9):1304-10
pubmed: 15869875
J Clin Oncol. 2015 Aug 20;33(24):2646-54
pubmed: 26169613
Childs Nerv Syst. 2013 Jul;29(7):1107-12
pubmed: 23595805
N Engl J Med. 2009 Sep 17;361(12):1164-72
pubmed: 19726763
Acta Neuropathol. 2013 Mar;125(3):359-71
pubmed: 23291781
Oncotarget. 2018 Jan 3;9(11):10175-10183
pubmed: 29515801
Acta Neuropathol Commun. 2019 Jul 30;7(1):123
pubmed: 31362788
Cancer Cell. 2015 Mar 9;27(3):327-41
pubmed: 25759019
Eur J Cancer. 2015 Nov;51(16):2434-43
pubmed: 26254812
Acta Neuropathol. 2019 Aug;138(2):327-330
pubmed: 31030238
Nature. 2012 Aug 2;488(7409):49-56
pubmed: 22832581